The study aimed to evaluate the impact of gastrectomy with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the outcomes of gastric cancer (GC) patients with limited peritoneal disease progression following neoadjuvant chemotherapy (NAC). Results showed that there was no survival benefit among advanced GC patients with peritoneal metastasis (PM) who underwent gastrectomy with CRS+HIPEC compared to those who underwent gastrectomy with CRS alone.
Journal Article by Kobiałka S, Sędłak K (…) Rawicz-Pruszyński K et 7 al. in J Clin Med